Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of The FloStent in Men Suffering From Benign Prostatic Hyperplasia Symptoms

NCT06849258 is registered in ClinicalTrials.gov with Rivermark Medical as lead sponsor.

NCT NCT06849258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06849258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of The FloStent in Men Suffering From Benign Prostatic Hyperplasia Symptoms
Lead sponsor
Rivermark Medical
Phase
Not applicable
Overall status
Recruiting
Start date
February 10, 2025
Completion date
December 31, 2032
Enrollment
215 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia